redirect destini cell therapi initi
initi coverag outperform rate pt
base belief fate induc pluripot stem cell ipsc technolog could
fundament disrupt emerg field cancer cell therapi autolog t-cell
therapi especi car-t offer lifelin patient aggress leukemia
lymphoma current suffer poor manufactur scalabl high
batch-to-batch variabl fate ipsc platform could serv renew effici
sourc off-the-shelf genet engin nk cell therapi view
next month potenti transform compani advanc
sever ipsc-deriv therapi clinic trial includ car-nk
could compet set cell therapi domin thu far
fate core compet lie proprietari methodolog direct cell
phenotyp function emphasi develop novel cell therapi
cancer compani ipsc platform could allow manufactur highli
optim nk cell therapi unpreced consist low cost
rel autolog patient-sourc product
advanc world first ipsc-deriv nk ink product
clinic two expect follow year nk cell versatil
tumor-kil may possess sever inher advantag cell adopt
nk cell therapi alreadi shown promis clinic fate ink approach
could potenti improv efficaci nk product
fate intern develop effort larg focus ink cell therapi
anticip first-in-human data later year next-gener
variant includ design modif
may help improv persist prevent tumor escap antigen loss
potenti extend reach nk cell therapi tumor type
ipsc platform could serv renew sourc gene-edit cell
therapi escap attent big biopharma last year ink
strateg collabor develop off-the-shelf car-
product agreement give ono option assum global develop
respons retain right co-develop co-commerci
us europ
valuat primarili center two engin ink program
slate enter clinic includ high-affin receptor
design improv natur anti-tumor activ nk cell
target car-nk believ partial de-risk encourag
data car-nk program md anderson
year price histori
inc
cancer immunolog disord
analyst certif import disclosur see disclosur
success clinic develop aml
commerci po
us eu sale
success clinic develop dlbcl
commerci po
us eu sale
success clinic develop protmun allo-hsct
commerci po
us eu protmun sale
better-than-expect market penetr rel
approv addit cell malign indic
cll
success develop commerci
takeout larg biopharmaceut compani increas
premium model assumpt
believ fate induc pluripot stem cell ipsc
technolog fundament disrupt emerg field
cancer cell therapi provid off-the-shelf therapi
valuat primarili center two ipsc-deriv product
aml dlbcl also includ
smaller contribut protmun non-ipsc cell
therapi intend improv outcom allogen stem cell
transplant due belief seriou unmet need
potenti file ind
potenti initi phase trial aml cell
potenti provid updat data on-going
potenti provid earli proof-of-concept
potenti announc top-line result protmun phase
failur key program advanc clinic develop
slower-than-expect develop timelin
lower-than-anticip market penetr key program
address patient popul model indic
competit
alter
price target base risk-adjust sum-of-th part npv contribut aml
dlbcl protmun allo-hsct includ fate project cash per share arriv target
risk includ price clinic regulatori financ market competit
clinical-stag biotechnolog compani base san
diego ca develop cellular therapi treatment cancer
high level fate pipelin segment cell sourc product
deriv healthi donor base induc pluripot stem cell ipsc
compani advanc clinical-stag product protmun
hematopoiet stem cell graft develop improv safeti allogen
ex vivo expand adopt nk cell therapi current test
three company-sponsor phase trial collabor univers
minnesota voyag aml apollo ovarian cancer dimens
fate earlier-stag program focu cellular therapi deriv ipsc
ipsc-deriv nk cell-bas treatment solid tumor recent
enter phase trial ipsc-deriv nk cell therapi optim
treatment liquid tumor intend use combin
antibodi includ rituximab elotuzimab ipsc-deriv
target chimer antigen receptor -nk develop collabor
univers california san diego ucsd could enter clinic
treatment cell malign final ipsc-
deriv car-t dub current develop collabor
memori sloan ketter cancer center mskcc slate enter
clinic
fate primari goal build better cell therapi treatment cancer
compani pipelin split non ipsc-deriv grow
list ipsc-deriv nk cell therapi compani entir pipelin built
around core compet use small-molecul modul control cell
phenotyp function view compani non ipsc-deriv program
protmun import valid fate abil
modul perform cell therapi howev believ fate pipelin
evolv favor ipsc-deriv product may subject
limit make tradit cell therapi challeng expens
produc larg scale
principl fate ipsc platform could repres renew cost-effect
new way manufactur off-the-shelf nk cell immunotherapi solid
liquid tumor renew sourc cell therapi high batch-to-
batch consist believ ipsc could transform cellular therapi
cancer potenti make reliabl predict access
patient last novemb receiv landmark clearanc fda
initi clinic trial first ipsc-deriv cell therapi enter human
fate ipsc-deriv pipelin includ sever product increas complex
simpler side ipsc-deriv nk cell therapi current
evalu patient solid tumor complex side
genet engin car-nk slate enter clinic nk cell
versatil tumor-kil adopt transfer nk cell healthi donor
cancer patient shown encourag sign efficaci tough-to-treat blood
cancer includ acut myeloid leukemia aml non-hodgkin lymphoma
thesi valuat larg center assess commerci
potenti two ipsc-deriv nk ink product
ipsc-deriv nk cell therapi liquid tumor lack construct
engin high-affin receptor design improv
natur anti-tumor activ rel unmodifi nk cell multipl academic-
sponsor trial demonstr clinic activ nk cell therapi
hematolog malign high-unmet need aml
car-nk product develop off-the-shelf altern
fda-approv car-t includ yescarta kymriah
believ car-nk cell recent valid academ investig
md report encourag clinic activ cell
malign first-in-human clinic data avail
plan develop ipsc-deriv cell therapi complement
ipsc-deriv nk cell product program current factor
valuat due earli develop stage
summar exhibit model includ contribut three
compani program relapsed/refractori aml po
commerci launch relapsed/refractori dlbcl
po commerci protmun match allo-hsct
po commerci launch
believ risk adjust larg line histor data
success rate drug base current stage develop natur
review drug discoveri elect use discount rate
program given inher riski drug develop
sum-of-part valuat two program summar
includ fate current cash posit per share total npv sum
round
exhibit part valuat mari
see upsid opportun sever avenu exampl estim
market opportun focus dlbcl one two
indic car-t current approv
pediatr believ potenti show benefit
cell malign includ cll mcl indol fl
invest thesi depend fate abil success develop
manufactur commerci cell therapi except
protmun assess fate product base sole preclin
evid rodent model variou cancer compani may also
experi slower-than-anticip complet clinic trial rel
abl success develop commerci cell therapi
product may face price pressur payer may also face ip-
relat risk product found infring issu patent
competit product believ mani technolog incorpor
product public domain
expect face intens competit compani vy creat
off-the-shelf cell therapi allogen cellecti major
development-stag biotechnolog compani abil maintain suffici
fund critic develop progress pipelin candid current
cash flow neg model multipl dilut rais
may necessari sustain oper compani potenti achiev
sustain profit
pipelin clinic program
potenti submit ind
potenti initi phase trial
potenti report initi data phase trial
potenti submit ind
potenti report earli data phase trial
potenti complet enrol protmun phase protect trial
potenti provid updat data on-going trial
potenti report top-line data protmun phase protect trial
compani present oppenheim co estim
rewrit destini cell therapi
unlik convent drug oncolog cell therapi hematopoiet
transplant car-t demonstr cur potenti heavili pre-
treat patient particularli suffer hematolog malign
allogen stem cell transplant allo-hsct use effect
year recent advanc transplant technolog improv safeti
procedur engin cell therapi car-t gener
strike result object respons rate orr exceed certain
despit cur potenti allo-hsct car-t therapi highli
person expens approach current avail method
sourc cell either directli patient healthi donor limit
scalabl product-to-product consist contribut high treatment
cost believ ipsc-deriv cell therapi address import
limit current avail cell therapi
summar fate approach exhibit use cocktail episom
transcript factor specif differenti cell
fibroblast coax pluripot stem cell state cours
day pluripot state cell serv precursor
cell type found bodi definit ipsc propag
indefinit undergo program differenti desir cell type
ipsc manipul knock key gene express newly-
introduc gene product construct prior re-differenti
exhibit overview ipsc technolog
adapt amabil meissner trend mol
pioneer cell therapi industri recogn potenti benefit
ipsc could offer convent sourc cell last decad
refin ipsc manufactur process robustli
reproduc convert donor-deriv fibroblast specif fetal foreskin
nearli unlimit suppli fulli differenti nk cell product key
differ fate approach vs convent cell therapi
requir genet manipul cell perform prior differenti
allow propag renew master cell bank
differenti ink product need differenti ink
cell final product cryopreserv thaw use
demand principl singl master cell bank could use support
commerci need entir product life cycl fate schema
manufactur ink product illustr exhibit
exhibit schema ink manufactur
view fate develop scalabl gmp-compliant ipsc platform
make true innov space compani overcom key
hurdl make technolog commerci viabl specif ipsc
notori difficult cultur singl cell make creation clonal
bank challeng addit ipsc natur tendenc differenti
unwant cell type cultur make manufactur
challeng found workabl solut problem
develop proprietari cultur condit media formul
expans mainten ipsc reprogram
mainten media describ stem cell report
impress fate product grown feeder-cel free condit
believ fate ipsc platform adequ protect combin
issu pend patent well trade secret
initi deploy ipsc platform creat off-the-shelf ink cell
therapi includ car-bas therapi car-t cell
engin express construct target cell defin tumor
antigen car-t made commerci debut establish
abil elicit durabl cure highli pretreat leukemia lymphoma
class believ car-t product potenti revolution
treatment sever hematolog malign howev recogn today
autolog patient-sourc car-t impart signific burden patient
provid payer alik believ limit could mitig
specif believ off-the-shelf solut batch-bas
manufactur product character perform up-front
repres natur evolut cell therapi manufactur patient-
sourc cell inher ineffici like contribut high
price case manufactur time critic
manufactur time may long certain patient aggress
cancer refer kite pharma gilead pivot trial
around patient drop due diseas progress wait
contrast highli person approach autolog car-t therapi
fate ipsc platform highli scalabl capabl deliv hundr
gmp-grade product singl manufactur run renew ipsc line
prepar compani phase trial singl harvest yield
suffici cryopreserv dose cell per dose potenti see phase
trial complet cell puriti measur marker
cell viabl post thaw
also note current avail autolog car-t high batch-to-
batch variabl may impact predict product safeti efficaci
heterogen mainli stem two variabl qualiti cell
collect cancer patient use autolog car-t
effici engin step exampl lentivir transduct
construct rang everi -t product curr opin
biotechnol principl use clonal ipsc master
cell bank would entir sidestep challeng
ipsc genet manipul perform cell state
nearli unlimit replic potenti aspect critic product
requir multipl engin step occur sequenti iter manner
exampl undifferenti ipsc could first fit
construct car-ipsc clone could select expans sequenti
modif introduct construct could
perform clone success incorpor desir modif
would includ master cell bank current avail tool
make homogen edit fulli differenti cell
versatil fate ipsc platform highlight exampl
compani gener clonal popul -t
construct specif insert trac genet locu trac
locu encod vital compon cell receptor tcr knock-in
simultan knocks-out tcr function prerequisit
off-the-shelf cell product character trac-target
present meet
importantli alon recogn commerci opportun off-
crispr other develop off-the-shelf product
healthi donor cell principl fate abil manufactur therapi
deriv singl cell clone could give compani advantag
competitor still must deal inher degre variabl end-
risk
common percept ipsc inher unstabl genom
lead accumul genet epigenet abnorm
chromosom sub-chromosom single-nucleotid level case
reprogram expand ipsc led oncogen transform
natur believ case may attribut use
c-myc well-character proto-oncogen cocktail transcript
factor use induc pluripot fate reprogram protocol
util c-myc extens preclin test product character
perform support ind applic suffici convinc
fda allow human test
introduc ink vanguard
novemb receiv clearanc fda initi clinic trial
first ipsc-deriv cell therapi enter human test februari
second clearanc grant separ ink product intend
hematolog malign product rel simpl compar
multi-edit car-nk could enter clinic
fate decis base initi ipsc-deriv product nk cell oppos
cell like born necess rather choic nk cell
rel easi differenti ipsc wherea cell typic undergo
complex educ process thymu difficult reproduc vitro
said nk cell prolif cancer cell killer believ possess mani
advantag properti cell could becom commerci viabl
product earli sign clinic activ nk cell product includ object
respons demonstr hand sever academ
highlight key differ nk cell
summar avail clinic data support use nk cell
hematolog malign addit compar fate ink cell
killer new class cell therapi
discov nk cell play uniqu role bridg innat
adapt immun unlik cell activ depend singl
antigen instead nk cell recogn molecular danger warn signal
express cell upon infect oncogen transform vitro nk
cell kill tumor cell effici cell could effect
situat tumor acquir resist adapt immun
respons physiolog nk cell complement cell function could
potenti deploy case cell mediat respons
inadequ tumor control mol feb
unlik cell innat arm immun nk cell exhibit degre
memori function possess multipl intrins kill mechan addit
convent granzym mediat cytotox importantli primari
mediat antibody-depend cellular cytotox adcc drive
activ antibodi rituximab engag receptor fate
ink modifi contain high-affin non-cleav
receptor intend boost efficaci combin therapeut antibodi
like rituximab nk cell regard shock troop immun
system engag tumor target initi durabl adapt immun
respons secret varieti pro-stimulatori cytokin upon activ
multipl effector function nk cell depict exhibit
nk cell major histocompat complex mhc -restrict mean
nk cell healthi donor readili transplant histolog
incompat host without risk trigger graft versu host diseas
gvhd facilit use nk cell adopt cell therapi
sever academ group biotech compani explor potenti
adopt nk cell therapi clinic set
exhibit nk cell clear tumor cell multipl mechan
bachanova et al present intern meet advanc malign lymphoma
clinic experi nk cell therapi
approach adopt nk cell therapi straightforward harvest nk cell
healthi donor expand number vitro infus
cancer patient ex vivo expans increas nk cell quantiti expand
cell alway retain essenti properti nk cell other
current optim cell cultur condit preserv nk cell qualiti
expans process sever nk cell product current
evalu clinic trial trial summar exhibit shown
evid clinic activ particularli aml nhl note trial
evalu expand nk cell therapi lack extens genet modif
target construct
donor-deriv product gener ipsc
instead nk cell harvest cytomegaloviru cmv -posit donor
cultur one week presenc inhibitor
manufactur process aim enrich nk cell
adapt memori phenotyp rel long persist
first describ fate collabor univers minnesota
current investig three on-going trial voyag
aml apollo ovarian cancer dimens mix solid tumor
combin inhibitor pool analysi three trial
present meet patient evalu efficaci
although object respons three four patient voyag
show transient reduct bone marrow blast dose-
limit toxic dose patient on-going second dose cohort
voyag third dose cohort apollo dimens
exhibit select clinic data adopt nk cell therapi trial
common characterist adopt nk cell therapi infus cell
limit persist bodytyp less two week given
limit persist nk cell believ multi-dos regimen may
requir unlock full potenti nk cell therapi unfortun
adopt nk cell therapi current face upper limit dose frequenc
exampl fate expans protocol typic yield total
nk cell per donor note ipsc-deriv ink product
would necessari limit manufactur constraint
similar ink nk
fate ink product origin fibroblast undergo differ
manufactur process rel convent adopt nk cell therapi
essenti compar phenotyp ink vs nk product despit matur
artifici environ fate ink display similar genet signatur donor-
deriv nk cluster convent expand nk cell princip
exhibit ink similar gene signatur peripher blood nk
importantli ink express mani marker convent nk cell
shown exhibit includ kir one except
activ receptor requir effect adcc function
express commonli associ nk cell matur potenc
blood due low express could
potenti display lower activ rel convent adopt nk cell
therapi howev preclin studi demonstr
appreci differ adopt nk cell therapi refer
aacr abstract regardless believ reduc express
ink may prompt includ high-affin non-cleav
variant second-gener ink
exhibit ipsc-deriv nk cell less surfac express
current evalu patient solid tumor fail
avail treatment option trial design summar
exhibit per protocol therapi administ two cycl
cycl consist three weekli dose precondit
fludarabine-cyclophosphamid flu-ci includ first cycl
commonli car-t protocol dose chase low-dos
per protocol three patient treat first dose cohort
cell per dose addit cohort receiv dose
cell respect announc asgct meet april
three patient first dose cohort success complet first cycl
treatment first patient recent consent combin
arm trial featur inhibitor
slate becom first gene engin ink enter clinic
previous mention engin express modifi variant
primari receptor respons activ adcc
pathway nk cell mediat kill mani commerci success monoclon
antibodi includ rituximab trastuzumab daratumumab reli adcc
function believ underscor import role
play drive tumor immun
variant includ includ two modif
intend improv efficaci see exhibit first antibody-bind domain
includ high affin fc bind variant present
roughli popul patient harbor variant
shown respond better adcc-engag therapi rituximab
antibodi modifi enhanc affin includ
obinatumumab margetuximab shown improv patient outcom
second modif remov proteas cleavag site extracellular
domain render resist inactiv
exhibit includ modifi version
preclin model addit high-affin non-cleav variant
improv efficaci specif rituximab better control tumor
growth aggress raji cell lymphoma model rel adopt nk cell
therapi rituximab see exhibit plan first investig
lymphoma combin rituximab multipl myeloma combin
elotuzumab pomalidomid anticip first-in-human trial
initi
exhibit modifi improv perform cell malign model
market opportun
base avail clinic data believ adopt nk cell therapi
shown clear sign efficaci relapsed/refractori aml cell malign
evid support use hematolog malign includ
multipl myeloma solid tumor indic less definit
believ may outperform clinic current model
sale model uptak r/r aml believ
opportun largest acknowledg may also activ
cell malign predict could offer better solut
aml common leukemia incid roughli new
case us year per seer statist approxim
expect achiev complet remiss induct chemotherapi relaps
major problem overal surviv rate hover around engl
believ could use option
primari refractori total relaps total patient
project could approv us eu
project combin peak sale repres market
penetr territori model assum list price
us eu believ less price
commerci avail car-t product market model aml
shown exhibit
exhibit market model aml
diagnos aml cases/year refractori cases/year relaps cases/year elig patient cost market size sale ex-royalti penetr treat diagnos aml cases/year refractori cases/year relaps cases/year elig patient cost market size sale ex-royalti penetr treat profit oper expens tax probabl discount revenu aml us eu therapeut
take aim cell malign
car-t includ gilead yescarta novarti kymriah
perform admir cell malign express high level
includ nhl fate first car-direct ink built
ground-up compet landscap domin cell therapi leverag
benefit ipsc platform includ multipl bell whistl
design optim activ includ high affin non-
cleavabl variant addit construct
principl construct could impart specif tumor cell
deploy combin b-cell specif antibodi
optim perform
design input fate academ collabor ucsd dr
kaufman base preclin work kaufman lab
demonstr transduc nk cell blunt
respons intracellular signal domain construct
optim compat nk cell cell stem cell aug
improv nk cell persist
modifi includ constitut activ receptor drive
prolifer shown extend surviv vitro
summar exhibit expand clonal modifi ipsc yield
high near uniform express desir modif
exhibit profil
derisk anoth car-nk
believ develop partial de-risk clinic
data emerg md anderson current evalu
car-nk deriv umbil cord blood ucb specif
car-nk develop dr kati rezvani shown impress clinic activ
on-going phase trial cell malign caveat small
single-cent studi md anderson car-nk shown orr compar
market car-t see exhibit like md anderson car-
nk product optim express self-activ receptor
stand md anderson car-nk preclin
base perform aggress raji cell lymphoma mous
model believ efficaci could par md
car-nk exhibit overal surviv similar mice treat
compar md anderson product although ucb-
deriv car-nk product appear control tumor growth slightli better less
outgrowth day howev subtl differ experi
could contribut differ exampl mice treat
ucb-deriv car-nk receiv higher dose versu cell
exhibit preclin efficaci eft md anderson car-nk right raji model
believ current avail car-t extrem
efficaci still see room improv exampl pivot
trial led approv yescarta dlbcl common
aggress subtyp nhl achiev initi respons although
month follow-up respons rate drop importantli loss
antigen tumor cell often found singl greatest contributor
diseas relaps nearli patient relaps
antigen loss mackal present deploy combin
tumor-specif antibodi like rituximab believ construct
express may effect impart second level tumor-target
specif current car-t product lack preclin experi
includ tumor cell dual-target function
combin rituximab essenti tumor control see exhibit
exhibit ad rituximab synerg anti-tumor efficaci
market opportun
base perform md anderson car-nk believ
could see commerci uptak dlbcl largest nhl
incid see avenu upsid estim prove
efficaci cell malign includ cll indol fl
per seer statist unit state approxim case new
nhl diagnos dlbcl largest nhl sub-typ
account nhl case per year blood jan
diseas curabl front line chemotherapi regimen typic r-
chop major patient howev relaps
chemo refractori induct chemo face poor prognosi autolog
stem cell transplant auto-hsct use lymphodeplet dose
chemotherapi standard care second line treatment option patient
relaps follow induct chemotherapi howev order qualifi
patient must chemo-sensit diseas
per elig criteria studi believ could
appropri patient healthi enough auto-hsct ecog statu
adequ organ function otherwis deem inelig
chemo-refractori diseas statu addit patient
relaps within month auto-hsct estim total us treatabl
popul approxim patient per year see
similarli eu estim total treatabl patient popul
project could approv us eu
project combin peak sale repres market
penetr territori model assum list price
us eu less price
commerci avail car-t product market model dlbcl
shown exhibit
exhibit market model dlbcl
nich transplant product pivot trial
invest commun larg fixat fate ipsc-deriv
therapi fate advanc asset quietli advanc late-stag
develop protmun hematopoiet stem cell graft optim
improv safeti allo-hsct potenti cur treatment
aggress blood cancer current enrol patient random
portion phase protect trial expect top-line data could
avail success believ protmun could becom gold
standard option stem cell transplant market opportun
estim us alon howev current assign low
po base limit clinic data seen program
protmun modifi stem cell graft harvest match sibl
unrel donor graft subject ex vivo modul two small
molecul prostaglandin
dexamethason enhanc biolog properti cell graft
preclin experi protmun transplant lower incid graft-
activ importantli increas incid relaps
protect trial current evalu protmun versu
unmanipul graft patient undergo allogen transplant
treatment aml cll md trial primari endpoint assess
cumul incid grade gvhd day support approv
expect fda requir least one year follow-up ensur
imbal rate relaps trial proceed random portion
diagnos dlbclcases/year us car-t elig dlbcl patient cost market size sale ex-royalti penetr treat diagnos dlbclcases/year eu car-t elig dlbcl patient cost market size sale ex-royalti penetr treat profit oper expens tax probabl discount revenu dlbcl us eu outperform
follow success complet lead-in safeti cohort shown
tabl exhibit graft failur day patient
aliv relaps free day two patient relaps
cumul incid day grade gvhd
view low incid relaps encourag believ small size
lead-in cohort limit interpret data refer believ
averag incid grade gvhd rang allo-hsct
popul per bone marrow tran blood
exhibit result lead-in cohort protect trial
market model protmun
accord estim cibmtr embt approxim
allogen stem cell transplant us eu
year around perform use either match relat
match unrel stem cell graft market segment
protmun current develop favor result protect
believ protmun could achiev moder penetr market
anticip product launch us eu assum price
us eu believ protmun could achiev peak
annual sale us eu market combin market model
shown exhibit believ current estim leav room upsid
protect success believ could expand protmun label
altern graft segment includ haploident graft deriv
umbil cord blood
exhibit market model protmun allo-hsct
therapeut acquir signific ip portfolio cover ipsc
technolog current includ issu pend
applic either own exclus licens note
exclus licens us patent cover method prepar
human ipsc requir c-myc overexpress revert pluripot
compani also exclus licens us patent
provid broad protect cell composit util overexpress
mean induc pluripot addit exclus licens
grant ucsd mskcc use construct engin
ipsc-deriv nk cell therapi respect
report cash equival quarter end march
estim could sustain oper ad multipl
dilut rais model total could sustain compani
profit growth estim
project loss
per share respect increas cash burn reflect
increas expens compani plan ind file
hscts/year match relat grafts/year match unrel grafts/year elig patient cost market size sale treat hscts/year match relat grafts/year match unrel grafts/year elig patient cost market size sale penetr treat profit oper expens tax probabl discount revenu hsct us eu outperform
believ protmun could approv commerci us eu
gener peak non-risk adjust annual sale
could approv commerci us eu
respect gener peak non-risk adjust sale
could approv commerci us eu
respect gener peak non-risk adjust sale
introduc estim increas
introduc estim increas
assum cog ipsc-deriv product
cog protmun believ line cost current
presid chief execut offic
mr wolchko presid chief execut offic
respons compani financ administr oper mr
wolchko began career invest banker co
serv six year firm new york citi menlo park
california offic member invest bank
group assist emerg growth compani health care
technolog sector complet capital-rais transact prior join
mr wolchko serv chief offic bocada
inc oversaw corpor service-rel oper previous
led corpor develop drugstor com respons
sourc evalu execut financi busi develop
opportun mr wolchko hold biochem engin
univers virginia biomed engin univers
dr shoemak chief scientif offic
overse compani discoveri preclin develop effort dr
shoemak previous chief scientif offic icx biosystem
led discoveri develop molecular tool enrich analyz rare cell
popul applic advanc detect technolog use
biodefens cancer prenat diagnost previous dr shoemak
chief scientif offic technolog acquir icx biosystem
led research develop rapid ultrasensit detect
assay biodefens clinic point-of-car diagnost
dr shoemak held variou posit increas respons merck
research laboratori mrknc includ director target discoveri senior
director rosetta inpharmat research fellow depart
molecular neurosci main focu target identif
biomark discoveri dr shoemak research merck result multipl
public top scientif journal includ natur scienc natur
dr shoemak receiv ph biochemistri stanford
univers biochemistri univers california santa
bahram bob valamehr chief develop offic
overse compani earli develop activ includ off-the-shelf cell
therapi product candid deriv compani induc pluripot stem
cell platform previous dr valamehr vice presid cancer
immunotherapi prior play key scientif role
center cell control nih nanomedicin develop center
broad stem cell research center develop novel method control
pluripot modul stem cell fate includ hematopoiesi better
understand cellular signal pathway associ cancer co-
author numer studi patent relat stem cell biolog oncolog
materi scienc dr valamehr receiv ph depart
molecular medic pharmacolog ucla pepperdin
univers depart chemistri biochemistri
sec file oppenheim co research
figur thousand except per share expens good sold research develop gener administr oper loss interest interest loss incom tax expens incom loss comprehens incom per share share outstand comatt therapeut
sec file oppenheim co research
figur thousand except per share cash account short-term invest relat matur prepaid expens current current properti equip oper leas right use restrict account payabl accru cirm award current portion defer oper leas liabil current long-term debt current current defer defer accru cirm award liabil long oper leas liabil net long-term debt net current prefer common paid-in comprehens stockhold liabil stockhold comatt outperform
stock price compani mention report close juli
